#United States #San Diego #Cenobamate #SK Life Science #XCOPRI

SK Life Science to Showcase XCOPRI® Results at AAN 2025

SK Life Science, Inc., a frontrunner in the development of central nervous system (CNS) disorder treatments, is set to present key findings on XCOPRI® (cenobamate tablets) during the upcoming 77th American Academy of Neurology (AAN) Annual Meeting, scheduled for April 5-9, 2025, in sunny San Diego, California. This presentation aims to shed light on the significant data regarding the medication's role in managing seizure activities and providing new insights into epilepsy treatment.

The AAN conference is one of the most prestigious platforms for neurological research, attracting experts and innovators from across the globe. This year, the emphasis lies heavily on XCOPRI, an anti-seizure medication that has recently garnered attention for its dual mechanism of action in reducing neuronal excitability. According to Louis Ferrari, the Vice President of Medical Affairs at SK Life Science, redefining the landscape of seizure management is crucial, especially for those who continually strive for seizure freedom.

At the heart of their presentation is a retrospective multicenter study which observed the effects of cenobamate on patients experiencing uncontrolled seizures. Over a span of 24 weeks, 37 participants reported substantial reductions in both epileptiform events and clinically observed seizures when treated with cenobamate. This data is crucial, emphasizing cenobamate as a vital therapeutic option for patients suffering from focal seizures.

The efficacy of cenobamate will be showcased through various poster presentations at AAN 2025. Notable sessions include studies that highlight the impact of cenobamate on responsive neurostimulation (RNS) and its effectiveness across diverse patient populations.

Some of the posters set for presentation at the conference include:

• - The Effect of Cenobamate on RNS Epileptiform Events by Aboumatar et al.
• - A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Adjunctive Cenobamate in Asian patients with focal seizures by Misra et al.
• - Early Response Rates With Adjunctive Cenobamate in uncontrolled focal seizures by Pradhan et al.
• - Clarification of the Mechanism of Action of Cenobamate by Sankar et al.

Moreover, SK Life Science will maintain an exhibit booth (#223) from April 6 to 9, where attendees can engage with the company’s team and learn more about their ongoing research and commitment to enhancing patient care in epilepsy therapy.

With rising disease awareness and the continuous efforts by SK Life Science to contribute to the scientific community, the insights presented at AAN 2025 promise to solidify cenobamate's standing as a noteworthy treatment in the realm of epilepsy management.

For those looking to understand the innovations behind cenobamate, visiting the SK Life Science booth will provide an opportunity to gain further understanding and highlight their mission to transform lives for those affected by CNS disorders.

As epilepsy remains a complex condition, affecting approximately 3.4 million individuals in the United States alone, the ongoing commitment to research and development from companies like SK Life Science is essential in striving toward better treatment solutions and engaging with the epilepsy community. By facilitating dialogue about their research and showcasing compelling clinical evidence, SK Life Science aims to continue positioning cenobamate as a critical player in the battle against seizures and improving patients’ quality of life.

For further insights into SK Life Science and their advancements in drug therapies, visit SK Life Science’s website.